Insider Transactions in Q3 2024 at Catalent, Inc. (CTLT)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2024
|
David Mc Erlane Group President, Biologics |
SELL
Open market or private sale
|
Direct |
1,994
-5.21%
|
$117,646
$59.97 P/Share
|
|
Aug 02
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
662
-2.16%
|
$39,058
$59.56 P/Share
|
|
Aug 02
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
666
-1.65%
|
$39,294
$59.55 P/Share
|
|
Aug 02
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
SELL
Open market or private sale
|
Direct |
608
-2.44%
|
$35,872
$59.58 P/Share
|
|
Aug 02
2024
|
Lisa Evoli SVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
3,859
-8.93%
|
$227,681
$59.67 P/Share
|
|
Aug 02
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
1,169
-1.02%
|
$68,971
$59.55 P/Share
|
|
Jul 29
2024
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
9,088
-4.87%
|
$527,104
$58.76 P/Share
|
|
Jul 29
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
206
-0.67%
|
$11,948
$58.67 P/Share
|
|
Jul 29
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
283
-0.7%
|
$16,414
$58.69 P/Share
|
|
Jul 29
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
349
-0.3%
|
$20,242
$58.7 P/Share
|
|
Jul 26
2024
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
63,736
+44.36%
|
-
|
|
Jul 26
2024
|
Michael Hatzfeld Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,624
+29.36%
|
-
|
|
Jul 26
2024
|
David Mc Erlane Group President, Biologics |
BUY
Grant, award, or other acquisition
|
Direct |
18,746
+32.86%
|
-
|
|
Jul 26
2024
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
17,042
+40.64%
|
-
|
|
Jul 26
2024
|
Lisa Evoli SVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,338
+26.19%
|
-
|
|
Jul 26
2024
|
Matti Masanovich SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,604
+35.78%
|
-
|
|
Jul 26
2024
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,671
+34.59%
|
-
|
|
Jul 26
2024
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
10,225
+24.9%
|
-
|
|
Jul 26
2024
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
11,078
+21.44%
|
-
|
|
Jul 26
2024
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
18,746
+13.99%
|
-
|
|
Jul 08
2024
|
Matti Masanovich SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,993
-8.12%
|
$167,608
$56.74 P/Share
|